Phyo, Aung Zaw Zaw
,
Ryan, Joanne
Gonzalez-Chica, David A.
Woods, Robyn L.
Reid, Christopher M.
Nelson, Mark R.
Murray, Anne M.
Gasevic, Danijela
Stocks, Nigel P.
Freak-Poli, Rosanne http://orcid.org/0000-0003-4072-8699
Funding for this research was provided by:
Rosanne Freak-Poli received a National Heart Foundation of Australia Postdoctoral Fellowship. (101927)
the National Institute on Aging and the National Cancer Institute at the National Institutes of Health (U01AG029824)
the National Health and Medical Research Council of Australia (334047, 1127060)
Monash University (Australia) and the Victorian Cancer Agency (www.aspree.org)
Other funding resources and collaborating organizations of the ASPREE study (www.aspree.org)
Monash International Tuition Scholarship (Medicine, Nursing, and Health Sciences) and Monash Graduate Scholarship (30072360)
Joanne Ryan received a National Health and Medical Research Council Dementia Research Leader Fellowship (APP 1135727)
Christopher M. Reid received Principal Research Fellowship (APP1136372)
Article History
Accepted: 24 November 2020
First Online: 3 January 2021
Compliance with ethical standards
:
: The authors declare that they have no conflict of interest.
: ASPREE (ASPirin in Reducing Events in the Elderly) trial is being conducted in accordance with the Declaration of Helsinki 1964 as revised in 2008, the NHMRC Guidelines on Human Experimentation, the federal patient privacy (HIPAA) law and ICH-GCP guidelines and the International Conference of Harmonization Guidelines for Good Clinical Practice. ASPREE also follows the Code of Federal Regulations as it relates to areas of clinical research. The overall management and conduct of the ASPREE clinical trial is the responsibility of the ASPREE Steering Committee. The data of the present secondary data-analysis study was from a five-year ASPREE clinical trial (Trial Registration: International Standard Randomized Controlled Trial Number Register (ISRCTN 83772183) and clinicaltrials.gov (NCT 01038583)). The current secondary data analysis has been approved by the Monash University Human Research Ethics Committee (project ID: 21714). The ASPREE trial has been approved by multiple Institutional Review Boards in Australia and the U.S. (ExternalRef removed).
: This study used data from a five-year ASPREE (ASPirin in Reducing Events in the Elderly) clinical trial (Trial Registration: International Standard Randomized Controlled Trial Number Register (ISRCTN 83772183) and clinicaltrials.gov (NCT 01038583)). All individual participants of ASPREE clinical trial signed informed consent on participation.
: All authors gave their approval for submission.